# Final QA — Q0492–Q0531

Date: 2026-08-14
Scope: V2-Q0492 through V2-Q0531 (40 standalone NCLEX-RN items)
Reviewer: OpenAI clinical/source audit

## Final QA result

Batch final-gate result: **PASS 40/40**
Full-bank commercial release gate: **CLOSED**

All 40 items were re-reviewed for keyed-answer correctness, clinical plausibility, rationale consistency, source relevance/currentness, distractor defensibility, ambiguity/overbreadth, and blueprint alignment. Final source-locator corrections identified during the final pass were versioned in `data/clinical_overrides_wave25i_final_source_fixes.json`.

## Final-source corrections

- V2-Q0506: specific Oncology Nursing Society Extravasation Management resource and section-level locator.
- V2-Q0507: current 2026 DailyMed albuterol label and adverse-effect section locator.
- V2-Q0522: NCBI Bookshelf Nursing Management and Professional Concepts, Chapter 4, Table 4.2b.
- V2-Q0524: NCBI Bookshelf Health Alterations, Chapter 12.5 Transition to Practice.
- V2-Q0529: 2026 GOLD Report/Pocket Guide source and report-level locator.

## Strict batch gate

The master now persists a dedicated `question_final_gate` record for every item Q0492–Q0531 with the following required dimensions:

- Source Verified: PASS
- Blueprint Verified: PASS
- Question Quality Verified: PASS
- Correct Answer Verified: PASS
- Distractors Verified: PASS
- Explanation Verified: PASS
- Currentness Verified: PASS
- Independent QA pass: PASS
- No unresolved conflict: PASS
- Source locator: persisted per item
- Source version/currentness record: persisted per item
- Auditor identity: persisted per item
- Rejection reason: persisted when applicable; NULL for this passing batch
- Option-length metrics: persisted per item for traceability

Batch metadata: `wave25_q0492_q0531_final_gate = PASS_40_OF_40_2026_08_14`.

## Governance boundary

This **PASS 40/40 applies only to Q0492–Q0531**. The full 3,525-item bank remains under the global commercial hard gate until the remaining items complete the same audit process. Therefore `commercial_release_ready` remains 0 at the full-bank level and the global gate remains CLOSED.

## Final disposition

Q0492–Q0531 are final-QA-passed batch items under the project's strict per-item gate. No unresolved conflict remains inside this 40-item batch. This status must not be interpreted as full-bank commercial release approval.
